← All indications
Anorexia
The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
Drugs by status
Approved for this indication (4)
Phase 3 trials (11)
Phase 2 trials (7)
Phase 1 trials (4)
Organizations
Organization Involved with Phase 4 Indications (12)
Organization Involved with Phase 3 Indications (37)
- Novo Nordisk
- Helsinn
- BioGaia AB
- Par Pharmaceuticals
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- MDCPharma Produtos Farmaceuticos LTDA
- Cairo University
- Canadian Cancer Trials Group
- Harvard University
- University of Ottawa
- University of Southern Denmark
- Wake Forest University
- University of Zagreb
- University of Zurich
- Mayo Clinic
- Department of Defense
- Government of Mexico
- University of Montpellier
- University of Lille
- Pharmaceutical Research Associates, Inc. (PRA)
- University of Texas at Houston
- Chengdu University of Traditional Chinese Medicines
- University of Sao Paulo
- University of Barcelona
- A Z Clinical Services LLC
- Dr. Felicio Savioli Clinical
- Pacific Cancer Medical Center Inc.
- University of Nantes
- +7 more
Organization Involved with Phase 2 Indications (47)
- McNeil
- Tercica
- Advanced Viral Research Corp
- Genentech
- Anaborex
- Endo Pharmaceuticals
- Motus Therapeutics, Inc.
- Cathay General Hospital
- Chang Gung University
- Changhua Christian Hospital
- Chung Shan Medical University
- Chimei Medical Center
- Faculdade de Medicina do ABC
- McGill University
- Multidisciplinary Association for Psychedelic Studies
- National Cheng Kung University
- Ohio State University
- Seoul National University
- University of Malaya
- University of South Florida
- University of Adelaide
- University of Alberta
- Taichung Veterans General Hospital
- Taipei Medical University
- University of Calgary
- University of California, San Diego
- University of Ulsan
- City University of Hong Kong
- OHR Pharmaceutical
- The University of Hong Kong
- +17 more
Organization Involved with Phase 1 Indications (12)
Organization Involved with Other Experimental Indications (14)
- University of Pittsburgh
- ARCIM Institute
- Cornell University
- Kyung Hee University
- University of Milan
- Laureate Institute for Brain Research
- Institute of Safety and Efficiency Evaluation for Korean Medicine
- University of Turin
- University of Lyon
- University of Oxford
- Diet4Life
- Brain & Behavior Research Foundation
- Government of France
- Filderklinik, Filderstadt, Germany